New York State Common Retirement Fund cut its holdings in shares of Emergent Biosolutions Inc (NYSE:EBS) by 8.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 76,818 shares of the biopharmaceutical company’s stock after selling 7,500 shares during the period. New York State Common Retirement Fund owned about 0.15% of Emergent Biosolutions worth $4,554,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the business. D.A. Davidson & CO. increased its stake in Emergent Biosolutions by 7.6% during the fourth quarter. D.A. Davidson & CO. now owns 3,667 shares of the biopharmaceutical company’s stock worth $217,000 after purchasing an additional 259 shares during the period. Huntington National Bank increased its stake in Emergent Biosolutions by 16.6% during the fourth quarter. Huntington National Bank now owns 2,633 shares of the biopharmaceutical company’s stock worth $156,000 after purchasing an additional 374 shares during the period. Quantamental Technologies LLC purchased a new stake in Emergent Biosolutions during the fourth quarter worth about $29,000. Piedmont Investment Advisors Inc. increased its stake in Emergent Biosolutions by 5.2% during the fourth quarter. Piedmont Investment Advisors Inc. now owns 10,781 shares of the biopharmaceutical company’s stock worth $639,000 after purchasing an additional 531 shares during the period. Finally, State of Alaska Department of Revenue increased its stake in Emergent Biosolutions by 5.2% during the fourth quarter. State of Alaska Department of Revenue now owns 14,989 shares of the biopharmaceutical company’s stock worth $888,000 after purchasing an additional 737 shares during the period. Institutional investors own 83.52% of the company’s stock.

EBS stock opened at $49.99 on Friday. The company has a debt-to-equity ratio of 0.78, a quick ratio of 2.07 and a current ratio of 3.10. Emergent Biosolutions Inc has a fifty-two week low of $46.93 and a fifty-two week high of $73.89. The company has a market cap of $2.59 billion, a P/E ratio of 21.45, a PEG ratio of 0.87 and a beta of 1.36.

Emergent Biosolutions (NYSE:EBS) last released its earnings results on Thursday, February 21st. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.61 by $0.14. Emergent Biosolutions had a net margin of 8.02% and a return on equity of 12.61%. The firm had revenue of $270.70 million for the quarter, compared to analyst estimates of $269.05 million. During the same period in the prior year, the firm earned $0.74 earnings per share. The business’s quarterly revenue was up 39.7% compared to the same quarter last year. Analysts anticipate that Emergent Biosolutions Inc will post 3.27 EPS for the current year.

A number of analysts recently weighed in on the stock. TheStreet lowered shares of Emergent Biosolutions from a “b+” rating to a “c+” rating in a research note on Tuesday, March 12th. Wells Fargo & Co set a $68.00 target price on shares of Emergent Biosolutions and gave the stock a “hold” rating in a research note on Friday, March 1st. ValuEngine lowered shares of Emergent Biosolutions from a “buy” rating to a “hold” rating in a research note on Friday, March 1st. Zacks Investment Research upgraded shares of Emergent Biosolutions from a “sell” rating to a “hold” rating in a research note on Thursday, February 28th. Finally, Chardan Capital set a $71.00 target price on shares of Emergent Biosolutions and gave the stock a “buy” rating in a research note on Friday, February 22nd. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $70.43.

In related news, EVP Adam Havey sold 2,430 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $56.93, for a total value of $138,339.90. Following the completion of the transaction, the executive vice president now directly owns 32,240 shares of the company’s stock, valued at $1,835,423.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Chairman Fuad El-Hibri sold 10,369 shares of the company’s stock in a transaction that occurred on Tuesday, February 26th. The shares were sold at an average price of $59.65, for a total value of $618,510.85. Following the completion of the transaction, the chairman now directly owns 1,478,306 shares of the company’s stock, valued at $88,180,952.90. The disclosure for this sale can be found here. Insiders sold 58,132 shares of company stock valued at $3,411,113 over the last ninety days. 13.40% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: “New York State Common Retirement Fund Sells 7,500 Shares of Emergent Biosolutions Inc (EBS)” was first reported by Marea Informative and is the property of of Marea Informative. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this piece of content can be read at https://www.mareainformativa.com/news/2019/03/17/new-york-state-common-retirement-fund-sells-7500-shares-of-emergent-biosolutions-inc-ebs.html.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases.

Read More: Cash Flow Analysis in Stock Selection

Institutional Ownership by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.